



# Oncnostics GmbH Presents New Clinical Data on GynTect® Precision Diagnostics at EUROGIN 2018

*Ocnostics will discuss new clinical data with gynaecological key opinion leaders at EUROGIN 2018*

SAN FRANCISCO, CA, USA, November 29, 2018 /EINPresswire.com/ -- Oncnostics GmbH presents new clinical data on GynTect® Precision Diagnostics for triage of unclear cervical cancer screening tests.



“We have concluded further clinical trials on the performance of GynTect® will present very convincing results at EUROGIN 2018”, states Dr. Alfred Hansel, Oncnostics Chief Executive Officer”

*Dr. Alfred Hansel*

Ocnostics GmbH, a Jena/Germany based company, has developed GynTect® for precision detection of cervical cancer. GynTect® was tested and validated in clinical trials on more than 3,000 samples with a remarkable detection score of 100% in all cervical cancer cases. Moreover, GynTect® identifies all relevant pre-cancerous lesions due to its first-of-a-kind prognostic value.

“We have concluded further clinical trials on the performance of GynTect® in comparison to alternative cervical cancer triage approaches. These results are very

convincing and we are happy to present them in 5 talks at the EUROGIN 2018 conference in Lisbon next week”, states Dr. Alfred Hansel, Oncnostics Chief Executive Officer.

Together with CSO Dr. Martina Schmitz and three Oncnostics R&D specialists for cervical cancer and head-and-neck cancer diagnostics, Oncnostics will discuss the new clinical data with gynecological key opinion leaders at Oncnostics booth for precision cancer diagnostics.

Ocnostics technology has been exclusively licensed out in 2017 to Sinopharm Group for the greater China region.

Biotech Alliances International Inc., a Silicon Valley-based healthcare-focused investment bank, is serving as the lead investment banker to Oncnostics globalization and partnering strategy. Meetings with Oncnostics Management Team can be coordinated at EUROGIN 2018 or JPM2019.

About Oncnostics GmbH

Ocnostics GmbH, founded in early 2012 as a spin-off from the Jena University women’s hospital, is a molecular diagnostics company specializing in cancer diagnostics. Oncnostics tests target epigenetic changes, so-called DNA methylations, that typically occur in cancer cells. The patented biomarkers, which are evaluated using a specific algorithm, are the core of the products and provide the basis for the company’s activities.

About Biotech Alliances International Inc.

Biotech Alliances International Inc. is a San Francisco-based investment bank serving life sciences companies, private equity, and venture capital funds. It provides independent financial

and strategic advice including corporate finance, mergers & acquisitions, partnering & licensing, and strategic consulting.

Dr. Franck Brinkhaus  
Biotech Alliances International Inc  
+1 650-868-8511  
[email us here](#)

---

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2018 IPD Group, Inc. All Right Reserved.